Michael White, PA
Physician Assistant · Boise, IDNPI 1780673707
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,813 of the $5,870 with a category attached, or 82.0%. 23 manufacturers reported payments, led by Medtronic at 46.2% of the total. Among physician assistant clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $50.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Tandem Diabetes Care, Inc.$684
- Abbott$393
- Insulet Corporation$322
- Corcept Therapeutics$299
- Lilly USA, LLC$179
- plus $1K from 17 others
What the payments were for
- Travel & lodging$1,05718%
- Food & beverage$4,81382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 39 | $2,714 |
| Tandem Diabetes Care, Inc. | 8 | $684 |
| Abbott | 15 | $393 |
| Insulet Corporation | 6 | $322 |
| Corcept Therapeutics | 7 | $299 |
| Lilly USA, LLC | 5 | $179 |
| Enterra Medical, Inc. | 1 | $156 |
| Johnson & Johnson | 1 | $149 |
| Boehringer Ingelheim | 3 | $146 |
| Bayer | 6 | $136 |
| Ascendis Pharma Endocrinology Inc | 2 | $134 |
| Dexcom, Inc. | 1 | $129 |
| Novo Nordisk | 5 | $77 |
| Recordati_rare_diseases_inc. | 3 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| Sequel Med Tech, LLC | 1 | $46 |
| IBSA Pharma Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Amgen | 2 | $32 |
| Averitas Pharma Inc. | 1 | $27 |
| EUSA Pharma (US) LLC | 1 | $23 |
| Echosens North America, Inc. | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INPEN SMART INSULIN DELIVERY SYSTEM$1,030
- MINIMED 780G$638
- t:slim X2 Insulin Pump with Control-IQ$386
- Korlym$242
- InPen$160
- FREESTYLE LIBRE 3$158
- Erleada$149
- AKEEGA$149
- DEXCOM G6 TRANSMITTER$129
- MOUNJARO$127
- Yorvipath$113
- JARDIANCE$111
How this compares
$5,870 in reported general payments places this provider in the 95th percentile of 1,027 physician assistant providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 91 | $144,336 |
| TrulicityDulaglutide | 75 | $116,527 |
| JardianceEmpagliflozin | 96 | $103,628 |
| OzempicSemaglutide | 53 | $71,988 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $51,735 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $28,365 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $25,760 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $22,518 |
| FarxigaDapagliflozin Propanediol | 22 | $21,738 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $12,926 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $12,619 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $11,560 |
| Novolog FlexpenInsulin Aspart | 36 | $9,221 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $7,506 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $7,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $179 | $268,631196 claims |
| Boehringer IngelheimJardiance | $146 | $103,62896 claims |
| Novo NordiskOzempic, Novolog | $77 | $78,63166 claims |
| Sanofi-aventis U.S. LLCLantus | $33 | $1,95118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,027 physician assistant providers in Idaho.
Other physician assistant in Boise
- Benjamin KernsBoise$100K
- Autumn HeumanBoise$28K
- Stuart ColdsnowBoise$8K
- Jeffrey SmithBoise$8K
- Stephanie RitariBoise$8K
- Michael LaneBoise$7K
- Daniel LeflerBoise$7K
- David KasamisBoise$6K
- Jessica SzwecBoise$6K
- Jaclyn GolusBoise$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.